| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 139,370 | 111,380 | 173,150 | 196,360 | 112,640 |
| Sales Growth | +25.13% | -35.67% | -11.82% | +74.33% | +37.70% |
| Net Income | -46,740 | -195,900 | -48,430 | 26,140 | -8,020 |
| Net Income Growth | +76.14% | -304.50% | -285.27% | +425.94% | +60.90% |
Oxford Biomedica Plc New (OXBDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom.
Fiscal Year End Date: 12/31